Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation
Diagnostics · 20.08.2026 · 16 (16) · 2660
DOI: 10.3390/diagnostics16162660 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 20.08.2026. Verfasst von Ting Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Tian Tan Hospital, Beijing Natural Science Foundation, Beijing Tiantan Hospital, Capital Medical University.
Abstract (Originalsprache)
Background
Diagnostic evaluation of suspected neuromyelitis optica spectrum disorder (NMOSD) integrates AQP4-IgG testing, clinical assessment, neuroimaging, and exclusion of alternative inflammatory demyelinating disorders; nevertheless, some patients remain diagnostically unresolved or may be misclassified as multiple sclerosis (MS) or other disorders.
Methods
This single-center retrospective exploratory study analyzed quantitative serum proteomics from 20 patients with MS and 20 with NMOSD. Proteins meeting nominal p < 0.05 together with prespecified fold-change criteria were considered exploratory candidates. VWF, PPBP, and SERPINA3 were subsequently assessed by ELISA in a separate, non-overlapping cohort from the same center, together with routine hematological variables.
Results
Among 261 protein entries, 34 met the exploratory nominal threshold and fold-change criteria, but none remained significant after Benjamini–Hochberg correction (lowest q = 0.0734). VWF and PPBP showed no significant differences across the four validation groups. SERPINA3 differed across groups (Kruskal–Wallis H = 44.982, p = 9.34 × 10−10) and was higher in NMOSD than in MS, TBI, and HCs after Holm adjustment (adjusted p = 0.036, 1.49 × 10−9, and 1.13 × 10−5, respectively). In the full ELISA cohort, the AUC was 0.928 for NMOSD versus HC and 0.800 for NMOSD versus MS. In a post hoc sensitivity analysis excluding participants with preceding infection, the NMOSD–MS separation was attenuated. In smaller complete-case analyses, adding an additional laboratory variable to SERPINA3 did not significantly improve apparent discrimination.
Conclusions
SERPINA3 is therefore an exploratory adjunctive serum biomarker candidate rather than a stand-alone diagnostic test; prospective external validation in clinically representative cohorts is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Diagnosis, Laboratory of Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
- Laboratory Diagnosis Platform for Nervous System Infectious Diseases, Laboratory for Clinical Medicine, Capital Medical University, Beijing 100070, China.
- Beijing Key Laboratory of Biomarker Screening and Translational Research in Neurological Diseases, Beijing 100070, China.
- The Fifth Clinical Medical School, Capital Medical University, Beijing 100070, China.
ORCID-Profile: Bingqing Han
Förderung
- Beijing Tian Tan Hospital
- Beijing Natural Science Foundation
- Beijing Tiantan Hospital, Capital Medical University
Zitieren
APA
Xu, T., Han, B., Zheng, G., Jiang, W., Zhang, H., & Zhang, G. (2026). Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation. Diagnostics, 16(16), 2660. https://doi.org/10.3390/diagnostics16162660
Vancouver
Xu T, Han B, Zheng G, Jiang W, Zhang H, Zhang G. Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation. Diagnostics. 2026;16(16):2660. doi:10.3390/diagnostics16162660
BibTeX
@article{Xu2026,
author = {Xu, Ting and Han, Bingqing and Zheng, Guanghui and Jiang, Wencan and Zhang, Hanyu and Zhang, Guojun},
title = {Serum SERPINA3 as a Candidate Non-Invasive Biomarker for Neuromyelitis Optica Spectrum Disorder: Proteomic Discovery and Same-Center Validation},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {16},
pages = {2660},
doi = {10.3390/diagnostics16162660}
}
EUVIMED